Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.trimurthidrugs.com | |
Market Cap | 8.30 Cr. | |
Enterprise Value(EV) | 8.30 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.07 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-03 |
Industry PE | 50.16 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 8.86 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 1.16 | Calculated using Price: 10.25 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.81 Cr. | 8,100,000 Shares |
FaceValue | 10 | |
About Trimurthi Ltd. | ||
Trimurthi Drugs & Pharmaceuticals is an India-based company. The Company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products. The Company's range of products include antibiotics, anti ulcer, anti inflammatory, antitussive/expectorant, cardiovascular, anti fungal, anti retroviral drugs, syrups and protein powder. The company since 1976 is built on the philosophy of commitment to quality and responsiveness. |
1 Day |
|
|
1 Week |
|
-4.21% |
1 Month |
|
-3.30% |
3 Month |
|
+14.91% |
6 Month |
|
+41.18% |
1 Year |
|
+13.89% |
2 Year |
|
+29.75% |
5 Year |
|
+36.67% |
10 Year |
|
-35.94% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 3.70 | 0.16 | 0.86 | 1.31 | 1.55 | 2.10 | 0.79 | -31.32 | -19.45 | |
Return on Capital Employed (%) | 5.46 | 0.81 | 1.20 | 1.78 | 2.50 | 1.60 | 0.89 | -31.33 | -19.51 | |
Return on Assets (%) | 3.54 | 0.16 | 0.85 | 1.29 | 1.50 | 2.04 | 0.78 | -31.42 | -19.56 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
Shh. Funds | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Minority Int. | |||||||||||
Equity & Liab. | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | |
Non Curr. Assets | 2 | 2 | 2 | 3 | 4 | 3 | 4 | 4 | 3 | 3 | |
Curr. Assets | 10 | 9 | 9 | 9 | 9 | 9 | 8 | 5 | 5 | 4 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. TTM |
Net Sales | 6 | 1 | 1 | 4 | 3 | 4 | 1 | 1 | 1 | 1 | |
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||
Total Income | 6 | 1 | 1 | 4 | 3 | 4 | 2 | 1 | 1 | 2 | |
Total Expenditure | -5 | -1 | -1 | -3 | -3 | -3 | -1 | -5 | -3 | -2 | |
PBIDT | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -1 | ||
Interest | 0 | ||||||||||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Exceptional Items | |||||||||||
PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | 0 | |
Adjusted EPS | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -4 | -2 | 0 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -3 | 0 | 0 | 2 | -1 | 1 | 0 | 1 | 1 | 1 | |
Cash Fr. Inv. | 1 | 1 | 0 | -2 | 1 | -1 | 0 | 0 | 0 | 0 | |
Cash Fr. Finan. | 2 | 0 | 0 | ||||||||
Net Change | 0 | 1 | -1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |
Cash & Cash Eqvt | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
Thu, 25 May 2023
Reg. 34 (1) Annual Report. Revised Annual Report for the year 2021-22 |
|||||||||||||||||||||
Mon, 01 May 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Publication of financial results |
|||||||||||||||||||||
Sun, 30 Apr 2023
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Nishitha Kalantri Designation: Company Secretary EmailId: info@trimurthidrugs.com Name of the Chief Financial Officer: Vani Manda Designation: CFO EmailId: info@trimurthidrugs.com Date: 30/04/2023 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
Wed, 31 May 2023 |
|
|
|
|
S Making Lower Lows for 2 Days |